SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing significant volatility and community debate after pulling its compounded GLP-1 drug amid a patent infringement lawsuit from Novo Nordisk and increased regulatory scrutiny. Investors are sharply divided between calls for a short squeeze and a rebound from oversold levels, and predictions of further downside due to ongoing legal and business model challenges.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is trending due to its all-stock acquisition of Valaris (VAL), a strategic consolidation that the community largely views as enhancing its market leadership and pricing power in an anticipated offshore drilling upcycle, though some express concerns over share dilution.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies ($PGY) is trending due to a significant market sell-off following its Q4 earnings, where conservative guidance for the coming year overshadowed stronger-than-expected profitability. The community is debating whether this reflects an extreme overreaction to management's focus on prudent risk management or a deeper concern within the AI-powered fintech sector.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is currently trending after its stock dramatically dropped following news of an SEC review into its accounting practices, reduced guidance, and the departure of its CFO and General Counsel. The community is sharply divided, with some calling it an extreme "overreaction" and a unique "buy-the-dip" opportunity, while others express severe concerns about potential financial improprieties, urging investors to "stay away" until more clarity emerges.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending as the community discusses its strategic acquisition of StereoLabs, which creates a unified lidar and camera platform for Physical AI applications. This move is largely seen as strengthening Ouster's market leadership and accelerating its path to profitability through StereoLabs' EBITDA-positive business.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending following a puzzling stock dip, which occurred despite strong earnings and raised guidance, prompting community discussion about whether an overreaction to its Super Bowl commercial or broader market sentiment is creating a 'buying opportunity'.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is experiencing a sharp sell-off after issuing a weaker-than-expected revenue outlook and withdrawing its long-term targets, intensifying broader market fears about AI disruption to the traditional software sector. Despite beating Q4 earnings, the community is divided between those viewing the steep decline as an overreaction and a buying opportunity, and others who believe AI poses a fundamental threat to the SaaS business model.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is trending as its Eversense 365 one-year implantable CGM recently received European CE Mark approval and integrated with the twiist automated insulin delivery system, signaling potential for expanded market access. While the community highlights the product's superior technology and opportunities from competitor issues, many investors express mixed sentiment due to concerns over management's commercial execution and historical stock performance.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

REGENXBIO is trending due to intense community speculation surrounding an imminent FDA decision on its RGX-121 gene therapy for Hunter Syndrome, as a recent clinical hold on the program and a related therapy, stemming from a serious adverse event, has many anticipating a Complete Response Letter or a regulatory delay.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as the community eagerly discusses the recently inaugurated Eagle Line pilot production facility, seen as a pivotal move towards scalable solid-state battery manufacturing and potential new OEM partnerships. Many anticipate its upcoming earnings report will provide crucial commercialization details, potentially fueling a significant market re-rate from current levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The results reinforce the device’s potential durability and support continued study in the pivotal REMAIN-1 trial.&nbsp;</li><li>Beyond weight maintenance, Revita-treated participants demonstrated improvements in lipid profiles.</li><li>Patient-reported outcomes also indicated reduced cravings for sweet foods.</li></ul>Fractyl Health, Inc. (GUTS) announced on Thursday positive six-month findings from its ongoing REMAIN-1 Midpoint Cohort, a study evaluating Revita for weight maintenance after patients discontinue GLP-1 therapy.The six-month data, covering 40 participants, suggest that Revita helps limit weight regain following GLP-1 discontinuation, with treated patients regaining 4.5% of weight versus 7.5% in the sham group.<h2 class="st-heading-2">Midpoint Study Shows Promising Results</h2>An exploratory analysis of those who lost above-median weight during the GLP-1 run-in showed a 70% relative reduction in post-GLP-1 weight regain for Revita-treated participants compared with sham.&nbsp;These results reinforce the device’s potential durability and support continued study in the pivotal REMAIN-1 trial. Beyond weight maintenance, Revita-treated participants demonstrated improvements in lipid profiles, including higher HDL cholesterol and a lower triglyceride-to-HDL ratio.&nbsp;Patient-reported outcomes also indicated reduced cravings for sweet foods, suggesting that the device may influence appetite and metabolism through gut-mediated mechanisms.However,&nbsp;<a href="https://stocktwits.com/symbol/GUTS">Fractyl Health's stock</a> plummeted 63% in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React</h2>Despite the fall in the stock’s price, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_29_085922_png_07f795b807.webp" alt="GUTS’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 29, 2026 | Source: Stocktwits" width="930" height="110"><figcaption>GUTS’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 29, 2026 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said the product that reduces sweet cravings could be extremely profitable, highlighting huge market potential.<stembedurl>https://stocktwits.com/BioRich/message/643264512</stembedurl>Another user said they trusted the management and would hold the stock.&nbsp;<stembedurl>https://stocktwits.com/CocoPeechu/message/643264755</stembedurl>Revita, the main product from Fractyl Health, is meant to reshape the lining of the small intestine through a single, minimally invasive procedure. The FDA has granted Revita Breakthrough Device designation to help people maintain weight after stopping GLP-1 treatments.The company also outlined upcoming catalysts, including one‑year cohort readouts and pivotal REMAIN‑1 data later this year, which could support a future U.S. marketing application.GUTS stock has declined by over 9% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-now-stock-is-falling/cmyifBjR4KZ">NOW Stock Falls 9% After Q4 Beat: Why Have Analysts Cut Price Targets?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study? 

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.

Equity

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.


<ul class="summary-bullets"><li>The patents issued cover critical aspects of Glucotrack’s implantable CBGM technology.</li><li>Unlike conventional CGM systems that sample glucose from interstitial fluid, Glucotrack’s device measures glucose directly from blood.</li><li>The long-term, fully implantable design offers more convenient option for diabetes management.</li></ul>Glucotrack, Inc. (GCTK) announced on Thursday that it has secured three new U.S. patents for its continuous blood glucose monitoring (CBGM) platform.&nbsp;The patents are expected to boost the company’s intellectual property portfolio as it moves its long-term implantable monitoring system closer to commercialization.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/GCTK">Glucotrack stock</a> traded over 12% higher in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">New Patents Strengthen IP</h2>The US Patent and Trademark Office issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258, covering critical aspects of Glucotrack’s implantable CBGM technology.The patents protect innovations in sensor chemistry, intravascular lead design, and low-power electronics, all integral to the company’s implantable system.On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day and message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Clinical And Practical Significance</h2>Unlike conventional CGM systems that sample glucose from interstitial fluid, Glucotrack’s device measures glucose directly from blood. This approach is expected to provide near real-time readings, eliminating the lag commonly seen with subcutaneous sensors.&nbsp;<blockquote>“Securing our intellectual property is fundamental to our strategy as we advance our fully implantable, long-term sensor through further clinical testing and toward commercialization.”-Paul V. Goode, President and CEO, Glucotrack</blockquote>The long-term, fully implantable design also aims to reduce patient burden and improve adherence, offering a potentially more convenient option for diabetes management.Glucotrack’s CBGM is a fully implantable device that tracks blood sugar continuously for up to three years. It does not require any wearable parts on the body and needs very little calibration.&nbsp;GCTK stock has declined by over 97% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-guts-stock-fell-revita-post-glp1-data/cmyig4sR4KA">Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A young girl suffering from diabetes type 1, squeezes air bubbles out of her catheter.

Why Did Glucotrack Stock Surge 12% Pre-Market Today?

The company has received patents for its continuous blood glucose monitoring system.

<ul class="summary-bullets"><li>The company went public in 2019 at a post-money valuation of $480 million, according to the report.&nbsp;</li><li>InMode has been facing declining sales and profits since 2023.</li><li>On January 9, the&nbsp;company said it anticipated its fourth-quarter sales to fall within a tight range of $103.6 million to $103.8 million.</li></ul>InMode stock became the talk of the town on Monday after a report stated that the company is set to be acquired by&nbsp;an investment fund in a deal that values the firm at roughly $1.1 billion, marking a 25% premium over its current Nasdaq trading value of $882 million.&nbsp;According to a Calcalist&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.calcalist.co.il/market/article/hjurxpfizl">report</a>, the transaction will result in InMode being taken private and removed from public trading.<a href="https://stocktwits.com/symbol/INMD">InMode stock</a> traded over 13% higher on Monday morning.&nbsp;<h2 class="st-heading-2">Background and Valuation</h2>Founded in 2008 by Moshe Mizrahi, the firm's CEO, and Michael Kreindel, the firm's Chief Technology Officer, the company originally developed advanced minimally invasive aesthetic treatments using radio frequency (RF) technology. It went public in 2019 at a post-money valuation of $480 million and reached a peak market value of $7 billion in 2021.Following the report, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘high’ message volume levels on Stocktwits.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_26_092338_png_08dfdb451a.webp" alt="INMD’s Sentiment Meter and Message Volume as of 09:40 a.m. ET on Jan. 26, 2026 | Source: Stocktwits" width="928" height="106"><figcaption>INMD’s Sentiment Meter and Message Volume as of 09:40 a.m. ET on Jan. 26, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Financial Challenges</h2>According to the report, InMode has been facing declining sales and profits since 2023, partly due to rising interest rates in the U.S. and an economic slowdown that affected financing for doctors purchasing its devices.&nbsp;The U.S. Food and Drug Administration’s (FDA) warning last October about health problems linked to some radiofrequency (RF) microneedling devices in general affected the stock.&nbsp;On January 9, the&nbsp;company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, below the analysts' consensus estimate of $104.64 million, according to FiscalAI data. Furthermore, the company’s 2025 revenue outlook of $370.2 million to $370.4 million is also below the analysts' consensus estimate of $371 million.INMD stock has declined by over 8% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crwv-stock-soars-nvidia-2-billion-investment-ai-infrastructure/cmy7qzrR4h2">CRWV Stock Soars 10% Pre-Market As Nvidia Invests $2B To Expand AI Factory Network</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 A worker produces medical instrument at Shandong Yixing Medical Instrument Co., Ltd.

INMD Stock Jumped Nearly 13% Today – What’s Powering The Rally?

According to a Calcalist report, the company is set to go private after a $1.1 billion acquisition by a fund. 

Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan

Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.

<ul class="summary-bullets"><li>The company sees 2025 revenue of $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.</li><li>BRIUMVI’s U.S. net product revenue expected to reach around $182 million in Q4 and $594 million in 2025.&nbsp;</li><li>TG Therapeutics stock rallies 9% higher in Wednesday’s premarket.&nbsp;</li></ul>TG Therapeutics, Inc. (TGTX) drew increased attention on Wednesday, with the stock seeing a 195% increase in retail chatter on Stocktwits over the last 24 hours following the company’s ambitious revenue outlook.&nbsp;On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.<h2 class="st-heading-2">What Did Stocktwits Users Say?&nbsp;</h2><a href="https://stocktwits.com/symbol/TGTX">TG Therapeutics stock</a> traded over 9% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_083034_png_390ef2e760.webp" alt="TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits" width="933" height="108"><figcaption>TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded optimistic about BRIUMVI achieving blockbuster status.<stembedurl>https://stocktwits.com/knowthyself/message/641747123</stembedurl>Another bullish user said the company’s ramp-up from Q3 to Q4 was impressive.&nbsp;<stembedurl>https://stocktwits.com/Uncle_Baby_Billy/message/641752748</stembedurl><h2 class="st-heading-2">Outlook Highlights&nbsp;</h2>TG Therapeutics expects BRIUMVI’s U.S. net product revenue to reach around $182 million in Q4 and $594 million for the full year of 2025. Global revenue for the year is estimated at $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.&nbsp;Looking ahead, the company anticipates total global revenue between $875 million and $900 million for 2026, with U.S. BRIUMVI sales projected at $825 million to $850 million.BRIUMVI is a glycoengineered monoclonal antibody that targets CD20-expressing B-cells, a proven approach for treating autoimmune diseases like relapsing multiple sclerosis (RMS). By removing specific sugar molecules, BRIUMVI enhances B-cell depletion at lower doses.<h2 class="st-heading-2">Upcoming Clinical Milestones</h2>The company also teased three major milestones for 2026.&nbsp;TG Therapeutics plans to release pivotal topline data for the ENHANCE trial, which evaluates Day 1 and Day 15 intravenous doses of BRIUMVI, by mid-2026. Preliminary Phase 1 data for azer-cel in Progressive multiple sclerosis (MS) will be shared in the latter half of the year.&nbsp;Pivotal topline results for subcutaneous BRIUMVI are expected by year-end 2026 or early 2027.&nbsp;TGTX stock has declined by over 6% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Biology lab technician removes a freeze-dried sample from a container in a laboratory.

Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.

<ul class="summary-bullets"><li>The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</li><li>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment.</li><li>Test volumes climbed to 18,000 in Q4 and 62,600 for the year.</li></ul>Biodesix Inc. (BDSX) stock surged over 23% in Monday’s premarket after the Colorado-based diagnostics firm provided a strong outlook for the fourth quarter (Q4) and fiscal year 2025.&nbsp;The company expects Q4 revenue of $28.8 million, a 41% year-over-year (YoY) increase, while full-year revenue is estimated at $88.5 million, up 24% YoY. The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Growth Driven By Lung Diagnostics</h2>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment, which is estimated to have generated $25.2 million in Q4 and $79.2 million for the full year. The results reflect a 47% and 22% YoY increase, respectively.&nbsp;Test volumes climbed to 18,000 in Q4 and 62,600 for the year, rising 23% and 15% from the previous year. The increase was driven by higher test volumes, stronger revenue per test, and about $1 million in collections from older claims.&nbsp;<blockquote>“Biodesix finished 2025 with a strong fourth quarter, delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million.”-Scott Hutton, CEO, Biodesix</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/BDSX">Biodesix stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_12_084117_png_27b632f1b5.webp" alt="BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Development Services&nbsp;</h2>The company’s development services segment contributed an estimated $3.6 million in Q4 and $9.3 million for 2025, representing growth of 13% and 41% over the prior year, respectively.&nbsp;“Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter,” added Hutton.&nbsp;Biodesix said it ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase over the previous quarter.&nbsp;BDSX stock declined by over 77% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-captures-20-of-global-smartphone-market/cmU96DMR4E4">Apple Captures 20% Of Global Smartphone Market, But Rising Memory Costs Cast Shadow On 2026 Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen.

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? 

The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.

This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why 

<ul class="summary-bullets"><li>Tempus’ 2025 Total Contract Value (TCV) exceeded $1.1 billion.</li><li>The 2025 agreement roster includes global pharma companies such as AstraZeneca, GlaxoSmithKline, and Pfizer.</li><li>Revenue from data and software-based offerings is expected to be approximately $316 million for 2025.</li></ul>Tempus AI, Inc. (TEM) stock gained over 11% in Monday’s premarket after the company reported that its Total Contract Value (TCV) surpassed $1.1 billion by the end of December 2025.Tempus uses artificial intelligence to work with large and diverse sets of medical data and provides tools that help doctors make more personalized treatment decisions.<h2 class="st-heading-2">Record Contract Growth</h2>Tempus secured data and analytics agreements with more than 70 organizations in the last year, showing the broad adoption of its multimodal data platform.&nbsp;The 2025 agreement roster spans global pharmas such as AstraZeneca, GlaxoSmithKline, Pfizer, Novartis, and Merck alongside biotech partners like Incyte and Whitehawk Therapeutics.&nbsp;<blockquote>“Our engagement with life sciences companies has never been stronger, and our data business has never been better positioned, giving us tremendous visibility to continued growth in 2026 and beyond.”-Jim Rogers, CFO, Tempus</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/TEM">Tempus AI stock</a> moved to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Retention And Revenue Strength</h2>Tempus also reported strong client retention, with net revenue retention around 126% as existing users increased their commitments in 2025.&nbsp;The company also released its outlook for both the fourth quarter (Q4) and the full year of 2025. For the year ending Dec. 31, 2025, Tempus expects total revenue to reach roughly $1.27 billion, a whopping 83% year-over-year increase. The company sees diagnostic testing as the primary growth engine, generating about $955 million in annual revenue.&nbsp;Revenue from data and software-based offerings is expected to be approximately $316 million for the year. For Q4, Tempus expects revenue to climb to nearly $367 million.&nbsp;TEM stock has gained over 104% in the last 12 months.&nbsp;Also See:<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slips-as-amazon-turns-up-heat-on-weight-loss-drugs/cmU9u36R43M"> Why Is HIMS Stock Slipping Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tempus AI logo is seen displayed on a smartphone screen.

Why Is Tempus AI Stock Surging 11% Premarket Today? 

Tempus secured data and analytics agreements with more than 70 organizations in 2025, showing the broad adoption of its multimodal data platform. 

<ul class="summary-bullets"><li>The firm is scheduled to report its financial performance for Q4 and fiscal 2025 ahead of the market open on Tuesday, Feb. 10, 2026.</li><li>The company’s total revenue for fiscal 2025 is projected around $370.2 million to $370.4 million.</li><li>Looking ahead, the company has set a revenue forecast for fiscal 2026 between $365 million and $375 million.</li></ul>InMode (INMD) stock is gaining investor attention in Friday’s premarket after the medical technology provider announced its fourth quarter (Q4) sales outlook.The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data.&nbsp;<h2 class="st-heading-2">2025 And 2026 Outlook&nbsp;</h2>The firm is scheduled to report its financial performance for Q4 and fiscal 2025 ahead of the market open on Tuesday, Feb. 10, 2026. The company’s total revenue for fiscal 2025 is projected to be around $370.2 million to $370.4 million, below the analysts' consensus estimate of $371 million, as per FiscalAI data.InMode expects a non-GAAP gross margin near the high end of the 70% range for the full 2025 fiscal year.&nbsp;Looking ahead, the company has set a revenue forecast for fiscal 2026 between approximately $365 million and $375 million.&nbsp;<a href="https://stocktwits.com/symbol/INMD">InMode stock</a> inched 0.8% higher in Friday’s premarket.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory while message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_09_055125_png_79a97af5f3.webp" alt="INMD’s Sentiment Meter and Message Volume as of 05:45 a.m. ET on Jan. 9, 2026 | Source: Stocktwits" width="926" height="105"></figure>A bullish Stocktwits user highlighted sequential growth and high margins.&nbsp;<stembedurl>https://stocktwits.com/thinkandpick/message/641307067</stembedurl>Another user pointed to ongoing pressure in the aesthetic device sector, noting that demand remains subdued, but added that the latest outlook broadly aligns with the company’s earlier outlook for 2025, suggesting performance is tracking as expected.<stembedurl>https://stocktwits.com/findingthestock/message/641285697</stembedurl><h2 class="st-heading-2">Brokerage Radar&nbsp;</h2>In December, Canaccord cut its price target on InMode to $15 from $16 and kept a ‘Hold’ rating on the stock, according to TheFly. The firm said it still has a positive long-term view on the medical technology industry going into 2026, noting that mid-sized company valuations remain low, and deal activity is increasing.INMD stock has declined by over 10% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-big-oil-invest-at-least-100-billion-venezuela/cmU29w3R4d2">Trump Says Big Oil Will Invest At Least $100 Billion To Rebuild Venezuela's Oil Infrastructure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

INMD Stock Draws Investor Attention On Q4 Financial Update

The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data. 

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

BlackRock Institutional Trust Company N.A. - iShares U.S. Medical Devices ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

IHI
iShares US Medical Devices ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IHI News

IHIiShares US Medical Devices ETF